Efavirenz: a review
SME Vrouenraets, FWNM Wit, J Tongeren… - Expert opinion on …, 2007 - Taylor & Francis
Efavirenz is a non-nucleoside reverse transcriptase inhibitor that in most treatment
guidelines is recommended to be taken combined with two nucleoside analogue reverse …
guidelines is recommended to be taken combined with two nucleoside analogue reverse …
Efavirenz: a decade of clinical experience in the treatment of HIV
F Maggiolo - Journal of Antimicrobial Chemotherapy, 2009 - academic.oup.com
Efavirenz, a non-nucleoside reverse transcriptase inhibitor, has been an important
component of the treatment of HIV infection for 10 years and has contributed significantly to …
component of the treatment of HIV infection for 10 years and has contributed significantly to …
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled …
JM Molina, P Cahn, B Grinsztejn, A Lazzarin, A Mills… - The Lancet, 2011 - thelancet.com
Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred
antiretroviral regimen for treatment-naive patients infected with HIV-1. Rilpivirine, a new non …
antiretroviral regimen for treatment-naive patients infected with HIV-1. Rilpivirine, a new non …
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a …
CJ Cohen, J Andrade-Villanueva, B Clotet, J Fourie… - The Lancet, 2011 - thelancet.com
Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine
(TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had equivalent sustained efficacy …
(TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had equivalent sustained efficacy …
CD4+ Cell Count 6 Years after Commencement of Highly Active Antiretroviral Therapy in Persons with Sustained Virologic Suppression
RD Moore, JC Keruly - Clinical infectious diseases, 2007 - academic.oup.com
Background. Sustained suppression of the human immunodeficiency virus (HIV) type 1 RNA
load with the use of highly active antiretroviral therapy (HAART) results in immunologic …
load with the use of highly active antiretroviral therapy (HAART) results in immunologic …
Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy
Objective: To characterize the temporal changes in mortality and life expectancy among HIV-
positive individuals initiating antiretroviral therapy in British Columbia, Canada, from 1993 to …
positive individuals initiating antiretroviral therapy in British Columbia, Canada, from 1993 to …
Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies
Background: Few data are available on the long-term immunologic response to antiretroviral
therapy (ART) in resource-limited settings, where ART is being rapidly scaled up using a …
therapy (ART) in resource-limited settings, where ART is being rapidly scaled up using a …
Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia …
Panel de Expertos de GeSIDA y Plan Nacional … - … y Microbiología Clínica, 2011 - Elsevier
La actualización de estas recomendaciones de tratamiento antirretroviral del adulto se han
consensuado por un panel de expertos del Grupo de Estudio de Sida y del Plan Nacional …
consensuado por un panel de expertos del Grupo de Estudio de Sida y del Plan Nacional …
[PDF][PDF] Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment
JM Llibre, B Clotet - Aids Rev, 2012 - researchgate.net
Once-daily single-tablet regimens represent the paramount simplification of antiretroviral
treatment achieved so far. They include drugs with favorable pharmacokinetics that allow …
treatment achieved so far. They include drugs with favorable pharmacokinetics that allow …
Early virological failure with a combination of tenofovir, didanosine and efavirenz
D Podzamczer, E Ferrer, JM Gatell, J Niubo… - Antiviral …, 2005 - journals.sagepub.com
Objective To describe the occurrence of a high early virological failure (VF) rate and
development of resistance mutations in antiretroviral-naive patients receiving tenofovir …
development of resistance mutations in antiretroviral-naive patients receiving tenofovir …